531210 COLINZ

Colinz Laboratories Share Price

 

 

Start SIP in COLINZ

Start SIP

Performance

  • Low
  • ₹45
  • High
  • ₹50
  • 52 Week Low
  • ₹36
  • 52 Week High
  • ₹89
  • Open Price₹46
  • Previous Close₹46
  • Volume4,141

Investment Returns

  • Over 1 Month + 15%
  • Over 3 Month + 13.19%
  • Over 6 Month -18.71%
  • Over 1 Year -31.47%

Smart Investing Starts Here Start SIP with Colinz Laboratories for Steady Growth!

Invest Now

Colinz Laboratories Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 25
  • PEG Ratio
  • -1.9
  • Market Cap Cr
  • 12
  • P/B Ratio
  • Average True Range
  • 3.97
  • EPS
  • -
  • Dividend Yield
  • 0
  • MACD Signal
  • 0.25
  • RSI
  • 62.42
  • MFI
  • 74.53

Colinz Laboratories Financials

Colinz Laboratories Technicals

EMA & SMA

Current Price
₹46.00
+ 0.15 (0.33%)
pointer
  • Bearish Moving Average 3
  • Bullish Moving Average 13
  • 20 Day
  • ₹42.76
  • 50 Day
  • ₹42.44
  • 100 Day
  • ₹43.83
  • 200 Day
  • ₹46.94

Resistance and Support

47 Pivot Speed
  • R3 53.98
  • R2 51.99
  • R1 48.99
  • S1 44.00
  • S2 42.01
  • S3 39.01

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Colinz Laboratories has an operating revenue of Rs. 5.87 Cr. on a trailing 12-month basis. An annual revenue de-growth of -6% needs improvement, Pre-tax margin of 9% is okay, ROE of 5% is fair but needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. From an O'Neil Methodology perspective, the stock has an EPS Rank of 68 which is a FAIR score but needs to improve its earnings, a RS Rating of 44 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 50 indicates it belongs to a fair industry group of Medical-Generic Drugs and a Master Score of D is close to being the worst. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment. Please note that this is a thinly traded stock.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Colinz Laboratories Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-27 Others Inter-alia to approve appointment of Ms. Falguni Kumawat as the Company Secretary and Compliance Officer of the Company and Key Managerial Personnel of the Company.
2025-11-11 Others Inter-alia, to approve appointment of Smt. Vijaya Mani (DIN 11363910) as Additional (Non- Executive) Director of the Company.
2025-11-03 Quarterly Results
2025-07-31 Quarterly Results
2025-05-16 Audited Results

Colinz Laboratories F&O

Colinz Laboratories Shareholding Pattern

66%
30.97%
3.03%

Colinz Laboratories FAQs

Colinz Laboratories share price is ₹46 As on 13 December, 2025 | 19:35

The Market Cap of Colinz Laboratories is ₹11.6 Cr As on 13 December, 2025 | 19:35

The P/E ratio of Colinz Laboratories is 25 As on 13 December, 2025 | 19:35

The PB ratio of Colinz Laboratories is 1.2 As on 13 December, 2025 | 19:35

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23